Injury characteristics and von Willebrand factor for the prediction of acute respiratory distress syndrome in patients with burn injury development and internal validation

Annals of Surgery

Volumn 270, Issue 6, 2019, Pages 1186-1193

  Afshar, Majid ^a,b   Burnham, Ellen L ^c   Joyce, Cara ^a   Gagnon, Robin ^a   Dunn, Robert ^a   Albright, Joslyn M ^d   Ramirez, Luis ^a   Repine, John E ^e   Netzer, Giora ^f   Kovacs, Elizabeth J ^c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d ADVOCATE CHRIST MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Biomarkers; Burn center; Inhalation burn; Von Willebrand

Indexed keywords

BIOLOGICAL MARKER; INTERCELLULAR ADHESION MOLECULE 1; RECOMBINANT VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; BLOOD LEVEL; BURN PATIENT; BURN UNIT; CALIBRATION; CLINICAL OUTCOME; ENDOTHELIUM INJURY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPOVOLEMIA; INFLAMMATION; LIMIT OF DETECTION; LUNG BURN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TIDAL VOLUME; AGED; BLOOD; BURN; CLINICAL TRIAL; COMPLICATION; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; REPRODUCIBILITY;

ADULT; AGED; BIOMARKERS; BURNS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 85074965775     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002795     Document Type: Article

References (51)

1. Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370:2191–2200.
2. Matthay MA, Brower RG, Carson S, et al. Randomized, placebo-controlled clinical trial of an aerosolized beta(2)-agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011;184:561–568.
3. Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327–336.
4. Morris PE, Papadakos P, Russell JA, et al. A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome. Crit Care Med. 2008;36:782–788.
5. Thompson BT, Bernard GR. ARDS Network (NHLBI) studies: successes and challenges in ARDS clinical research. Crit Care Clin. 2011;27:459–468.
6. Trillo-Alvarez C, Cartin-Ceba R, Kor DJ, et al. Acute lung injury prediction score: derivation and validation in a population-based sample. Eur Respir J. 2011;37:604–609.
7. Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med. 2011;183:462–470.
8. 2014 National Burn Repository: Report of Data From 2004–2013. In: Association AB, ed. 10.0 ed. Chicago, IL: National Burn Repository; 2014.
9. Belenkiy SM, Buel AR, Cannon JW, et al. Acute respiratory distress syndrome in wartime military burns: application of the Berlin criteria. J Trauma Acute Care Surg. 2014;76:821–827.
10. Cartotto R, Li Z, Hanna S, et al. The Acute Respiratory Distress Syndrome (ARDS) in mechanically ventilated burn patients: An analysis of risk factors, clinical features, and outcomes using the Berlin ARDS definition. Burns. 2016;42:1423–1432.
11. Rogers AJ, Matthay MA. Applying metabolomics to uncover novel biology in ARDS. Am J Physiol Lung Cell Mol Physiol. 2014;306:L957–961.
12. Kor DJ, Carter RE, Park PK, et al. Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A Randomized Clinical Trial. JAMA. 2016;315:2406–2414.
13. Matthay MA, McAuley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med. 2017; 5:524–534.
14. Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611–620.
15. Zhao Z, Wickersham N, Kangelaris KN, et al. External validation of a biomarker and clinical prediction model for hospital mortality in acute respiratory distress syndrome. Intensive Care Med. 2017;43:1123–1131.
16. Calfee CS, Ware LB, Glidden DV, et al. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Critical Care Med. 2011;39:711–717.
17. Fremont RD, Koyama T, Calfee CS, et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma Acute Care Surg. 2010;68:1121–1127.
18. Binnie A, Tsang JL, dos Santos CC. Biomarkers in acute respiratory distress syndrome. Curr Opin Crit Care. 2014;20:47–55.
19. ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307:2526–2533.
20. Mosier MJ, Pham TN, Park DR, et al. Predictive value of bronchoscopy in assessing the severity of inhalation injury. J Burn Care Res. 2012;33:65–73.
21. Heng JS, Clancy O, Atkins J, et al. Revised Baux Score and updated Charlson comorbidity index are independently associated with mortality in burns intensive care patients. Burns. 2015;41:1420–1427.
22. Dokter J, Meijs J, Oen IM, et al. External validation of the revised Baux score for the prediction of mortality in patients with acute burn injury. J Trauma Acute Care Surg. 2014;76:840–845.
23. Saunders JB, Aasland OG, Babor TF, et al. Development of the alcohol use disorders identification test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption—II. Addiction. 1993;88:791–804.
24. Afshar M, Burnham EL, Joyce C, et al. Cut-point levels of phosphatidylethanol to identify alcohol misuse in a mixed cohort including critically ill patients. Alcohol Clin Exp Res. 2017;41:1745–1753.
25. Afshar M, Smith GS, Terrin ML, et al. Blood alcohol content, injury severity, and adult respiratory distress syndrome. J Trauma Acute Care Surg. 2014;76:1447–1455.
26. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42:377–381.
27. Ware LB, Eisner MD, Thompson BT, et al. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med. 2004;170:766–772.
28. Ware LB, Conner ER, Matthay MA. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med. 2001;29:2325–2331.
29. Calfee CS, Eisner MD, Parsons PE, et al. Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. Intensive Care Med. 2009;35:248–257.
30. Conner ER, Ware LB, Modin G, et al. Elevated pulmonary edema fluid concentrations of soluble intercellular adhesion molecule-1 in patients with acute lung injury: biological and clinical significance. Chest. 1999;116(1 suppl):83S–84S.
31. Eisner MD, Parsons P, Matthay MA, et al. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003;58: 983–988.
32. Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest. 2010;137:288–296.
33. Parsons PE, Matthay MA, Ware LB, et al. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288:L426–431.
34. Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to the active conformtion of von Willebrand factor and blocks the interaction with glycoprotein Ibalpha. J Thromb Haemost. 2007;5:1363–1370.
35. Baldauf C, Schneppenheim R, Stackliew W, et al. Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis. J Thromb Haemost. 2009;7:2096–2105.
36. Steyerberg EW, Harrell FE Jr, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774–781.
37. Burnham EL, Moss M. Alcohol abuse in the critically ill patient. Lancet. 2006;368:2231–2242.
38. Moss M, Parsons PE, Steinberg KP, et al. Chronic alcohol abuse is associated with an increased incidence of acute respiratory distress syndrome and severity of multiple organ dysfunction in patients with septic shock. Crit Care Med. 2003;31:869–877.
39. Rubenfeld GD, Peabody E, Weaver J, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685–1693.
40. Sarkar K, Rey S, Zhang X, et al. Tie2-dependent knockout of HIF-1 impairs burn wound vascularization and homing of bone marrow-derived angiogenic cells. Cardiovasc Res. 2012;93:162–169.
41. Gritti G, Cortelezzi A, Bucciarelli P, et al. Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis. Am J Hematol. 2011;86:650–656.
42. Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117:1071–1080.
43. Zhang X, Wei X, Liu L, et al. Association of increasing burn severity in mice with delayed mobilization of circulating angiogenic cells. Arch Surg. 2010;145:259–266.
44. Honiden S, Gong MN. Diabetes, insulin, and development of acute lung injury. Crit Care Med. 2009;37:2455–2464.
45. Calfee CS, Eisner MD, Ware LB, et al. Trauma-associated lung injury differs clinically and biologically from acute lung injury owing to other clinical disorders. Crit Care Med. 2007;35:2243–2250.
46. Reper P, Heijmans W. High-frequency percussive ventilation and initial biomarker levels of lung injury in patients with minor burns after smoke inhalation injury. Burns. 2015;41:65–70.
47. Oto B, Orosco RI, Panter E, et al. Prone positioning of the burn patient with acute respiratory distress syndrome: a review of the evidence and practical considerations. J Burn Care Res. 2017 [Epub ahead of print].
48. Kennedy JD, Thayer W, Beuno R, et al. ECMO in major burn patients: feasibility and considerations when multiple modes of mechanical ventilation fail. Burns Trauma. 2017;5:20.
49. Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. New Engl J Med. 2015;372:747–755.
50. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intenstive care units in 50 countries. JAMA. 2016;315:788–800.
51. Tricklebank S. Modern trends in fluid therapy for burns. Burns. 2010;35: 757–767.